Ann: Converting Note & Non-Renounceable Entitlement Offer, page-31

@oom10

I have covered this in many of my earlier posts on MEB when I went to the investor meetings... Not sure if you attended them.

It was relevant with what VC bought to the table and the IP - and why MEB alone was a tough sell in terms of how the medical / psychology specialties approached new technology and why MEB alone was likely not to succeed, other than as a Fitbit non medical attachment.

That is still a big issue... perhaps flick back to my previous posts and I think everyone who went to those meetings got the clinical picture.

As for loss making - VC had a lot of IP they had developed, a marketing strategy - and it cant have been that bad with what VC / Peta achieved for MEB in terms of income in the short few months after acquisition.  Perhaps wait until the next quarterly and see if that momentum of income has been maintained... 

and yes - it has been tough for all and I am not yet convinced enough to re enter the share